Chugai Building On Roche Alliance Success As It Eyes Future: CEO Okuda
Digital Strategy Now In Focus
Executive Summary
In an exclusive interview with Scrip, Chugai's CEO says the now 20-year-old strategic partnership with Roche has been one of the keys to Chugai’s successful growth and has allowed smooth market expansion for both firms, as well as enabling R&D investment by the Japanese firm. A flexible, platform-based approach to R&D, rather than focusing on specific target diseases or technologies, has also benefitted Chugai, Osamu Okuda noted.
You may also be interested in...
Eyeing Agility, Astellas Expands Digital Transformation Initiative
Soon-to-start digital transformation initiatives at the major Japanese pharma firm will focus on in-housing of IT systems and company-wide enhancement of AI/data analytics skills.
Crovalimab Filed In Japan As More Phase III Results Released At EHA
The Chugai/Roche antibody has been filed for PNH in Japan as more details of its Phase III results are released.
Japan Q3 Roundup: Forex Impacts Majors Amid New Product Growth Expectations
Amid ongoing impact from exchange rates, Japan's five largest pharma firms showed mostly positive growth in the fiscal nine-month period. Enhertu will continue to drive Daiichi Sankyo, while Shionogi is forecasting record-breaking revenue on oral COVID-19 drug Xocova and Eisai is rolling out closely-watched Alzheimer's contender Leqembi.